This article was originally published in The Gray Sheet
Executive SummaryNational Institute for Clinical Excellence division of Britain's National Health Service receives appeal against development of a guidance on children's use of inhalers. The appeals board will meet Aug. 31 to consider the appeal. The institute's guidance would not be finished before mid-September but could be delayed pending the outcome of the appeal
You may also be interested in...
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.